{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:33:53Z","timestamp":1762864433155},"reference-count":21,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The antimicrobial activities of tigecycline (GAR-936) were compared with those of other agents against 1,087 strains recently isolated in 12 Spanish medical centers. Tigecycline showed activity against a wide spectrum of aerobic and anaerobic bacteria, including strains such as methicillin-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            , coagulase-negative staphylococci, penicillin-resistant\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            ,\n            <jats:italic>Enterococcus faecium<\/jats:italic>\n            ,\n            <jats:italic>Acinetobacter baumannii<\/jats:italic>\n            , and\n            <jats:italic>Stenotrophomonas maltophilia.<\/jats:italic>\n          <\/jats:p>","DOI":"10.1128\/aac.46.3.892-895.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T09:56:57Z","timestamp":1027763817000},"page":"892-895","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":81,"title":["In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in Spain"],"prefix":"10.1128","volume":"46","author":[{"given":"Carmen","family":"Betriu","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, Hospital Cli\u0301nico San Carlos"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iciar","family":"Rodri\u0301guez-Avial","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Hospital Cli\u0301nico San Carlos"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blas Ali","family":"Sa\u0301nchez","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Hospital Cli\u0301nico San Carlos"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u0301a","family":"Go\u0301mez","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Hospital Cli\u0301nico San Carlos"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"A\u0301lvarez","sequence":"additional","affiliation":[{"name":"Scientific Department, Wyeth Farma, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"Picazo","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Hospital Cli\u0301nico San Carlos"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.4.1238-1243.2001"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/BF01962077","volume":"11","year":"1992","unstructured":"Betriu, C., C. Cabronero, M. Gomez, and J. Picazo. 1992. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989. Eur. J. Clin. Microbiol. Infect. Dis.11:352-356.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2225-2229.2000"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199907223410403"},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1469-0691.2000.00034-6.x","volume":"6","year":"2000","unstructured":"Edlund, C., and C. Nord. 2000. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin. Microbiol. Infect.6:159-163.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(99)00092-9"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.9.2218"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1310"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","unstructured":"Hoellman D. B. G. A. Pankuch M. R. Jacobs and P. C. Appelbaum. 2000. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 44: 1085-1088.","DOI":"10.1128\/AAC.44.4.1085-1088.2000"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.11.4298-4299.2000"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"Antimicrob. Agents Chemother. 1999 43","DOI":"10.1128\/AAC.43.5.999"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/320185","volume":"32","year":"2001","unstructured":"Low, D. E., N. Keller, A. Barth, and R. N. Jones. 2001. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis.32(Suppl. 2):133-145.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.11.3022-3027.2000"},{"key":"e_1_3_3_15_2","unstructured":"National Committee for Clinical Laboratory Standards. 1997. Methods for antimicrobial susceptibility testing of anaerobic bacteria 4th ed. Approved standard M11-A4. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_3_16_2","unstructured":"National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_3_17_2","unstructured":"National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing. Eleventh informational supplement. M100-S11. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0732-8893(00)00193-0","volume":"38","year":"2000","unstructured":"Patel, R., M. Rouse, K. Piper, and J. Steckelberg. 2000. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis.38:177-179.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_3_19_2","first-page":"183","volume":"13","year":"1991","unstructured":"P\u00e9laez, M. T., E. Cercenado, M. Rodr\u00edguez-Creixems, and E. Bouza. 1991. Resistance of anaerobic bacteria to antimicrobial agents. Rev. Infect. Dis.13:183.","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s100960000360","volume":"19","year":"2000","unstructured":"Peset, V., P. Tallon, C. Sola, E. S\u00e1nchez, A. Sarrion, C. P\u00e9rez-Belles, A. Vindel, E. Canton, and M. Gobernado. 2000. Epidemiological, microbiological, clinical, and prognostic factors of bacteremia caused by high-level vancomycin-resistant Enterococcus species. Eur. J. Clin. Microbiol. Infect. Dis.19:742-749.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.738"},{"key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/jac\/43.3.431","volume":"43","year":"1999","unstructured":"Schmitz, F., J. Verhoef, and A. Fluit. 1999. Geographical distribution of quinolone resistance among Staphylococcus aureus, Escherichia coli and Klebsiella spp. isolates from 20 European university hospitals. SENTRY Participants Group. J. Antimicrob. Chemother.43:431-434.","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.3.892-895.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.3.892-895.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:39:53Z","timestamp":1645465193000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.46.3.892-895.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["10.1128\/AAC.46.3.892-895.2002"],"URL":"https:\/\/doi.org\/10.1128\/aac.46.3.892-895.2002","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]},"assertion":[{"value":"2001-08-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-12-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}